E beneficial as a non-invasive tool to confirm and subtype brain tumours in instances exactly where its place makes biopsies risky or not possible, for drug clinical trial enrollment, to facilitate early surgical planning, and to alter practice paradigms for GBM. Funding: This work was supported by the NIH grants UH3 TR000931 (BSC, LB) and P01 CA069246 (BSC).LBF06.Neural-derived peripheral biomarkers for antidepressant response from plasma exosomes Corina Nagy; Saumeh Saeedi-Tabar; Jean-Francois Theroux; Gustavo Turecki DMHUI, McGill University, Montreal, CanadaLBF06.Plasma-based detection of gliomas Sabrina Roy; Julia Compact; Elizabeth Lansbury; Leonora Balaj; Noah SadikBackground: Major depressive disorder (MDD) impacts millions of men and women worldwide; however, response to treatment is very variable, with only one-third of patients responding towards the first antidepressant they’re prescribed. Consequently, there has been a surge in investigation to uncover biomarkers of MDD remedy response. To date, most research inside the field has been performed in peripheral tissues, which, although helpful for biomarker discovery, limits the relevance of these findings towards the biology of psychiatric disease. Offered that exosomes can freely cross the bloodbrain barrier, neural-derived exosomes (NDE) identified in plasma can act as biomarkers, at the same time as offer details concerning central changesFriday, 04 Mayresulting from antidepressant drug response. MicroRNAs (miRNA) are a crucial class of exosomal cargo, which HPV E6 Proteins supplier likely influence the functioning of recipient cells. As such, differential NDE miRNA profiles can act as predictive biomarkers, at the same time as give mechanistic insight into adjustments which occur throughout antidepressant response. Approaches: For our pilot study, exosomes have been isolated from two ml of plasma from 10 controls and 10 MDD patients (5 responders, 5 nonresponders) applying a size-exclusion column from Izon Science (Christchurch, NZ). Each sample was divided to produce a “whole exosomes” fraction as well as a “neural-derived (NDE)” fraction, immunoprecipitated using the neural marker L1CAM. Fractions have been quantified and sized utilizing tunable resistive pulse sensing on the gNano gold, and RNA was extracted from L1CAM+ fraction and its depleted supernatant for library preparation utilizing the 4N-small RNA-Seq (Galas) VRK Serine/Threonine Kinase 1 Proteins Species protocol. A known plant miRNA was spiked-in to all samples for normalization and sequenced on the Illumina HiSeq platform. Results: We identified that NDE are smaller sized than the full pool of plasma exosomes. Exosomes from patients, no matter antidepressant response, are significantly smaller than controls in both the complete and NDE fractions. We have also identified a group of miRNAs that are hugely enriched inside the NDE fraction, and that overlap with miRNAs discovered in brain. Differential analyses show quite a few prospective targets for follow-up investigation. Summary/Conclusion: Isolating NDE from plasma gives an incredibly useful resource for biomarker discovery in MDD. We aim to work with exosomes to provide neural miRNA profiles of MDD drug response. Funding: This function was funded by CIHR.LBF06.Modulation of microglia responses via mesenchymal stromal cells derived-extracellular vesicles Dorota Kaniowska1; Kerstin Wenk2; Frank Emmrich1; Yarua Jaimes1 Fraunhofer Institute for Cellular Therapy and Immunology, Leipzig, Germany; 2Institute for Clinical Immunology, University of Leipzig, Leipzig, GermanyLBF06.Delivery of ribosomes from glia to neurons Andrea Schnatz1; Kerstin M ler2; Ch.